Press Releases & Statements

Investor Relations

Month Year

Month Year

Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing Quality
- Statement
- COVID-19
Oct 20, 2021
Novavax Statement on Initial Com-COV2 Phase 2 Clinical Trial Results Presented at World Vaccine Congress Europe
- Statement
- COVID-19
Oct 19, 2021
Novavax to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights on November 4, 2021
- Corporate and Finance
Oct 18, 2021
Novavax to Participate in World Vaccine Congress Europe
- COVID-19
- Seasonal Influenza
Oct 15, 2021
Complete PREVENT-19 Phase 3 Clinical Trial Results Manuscript for COVID-19 Vaccine Posted to medRxiv
- Statement
- COVID-19
Oct 11, 2021
Novavax Announces Leadership Appointment and Updates
- Corporate and Finance
Oct 4, 2021
Novavax to Participate in Health Equity and Vaccine Confidence Panel at Maryland Life Sciences Bio Innovation Conference
- COVID-19
Sep 29, 2021
Novavax Hosts HM King Carl XVI Gustaf and HM Queen Silvia of Sweden During Royal Visit to Uppsala County
- COVID-19
Sep 24, 2021
Results from Novavax NanoFlu Influenza Vaccine Phase 3 Clinical Trial Published in The Lancet Infectious Diseases
- Seasonal Influenza
Sep 23, 2021
Novavax and Serum Institute of India Announce Submission to World Health Organization for Emergency Use Listing of Novavax' COVID-19 Vaccine
- COVID-19
Sep 23, 2021

Show per page